An Exploratory Clinical Study to Evaluate the Safety and Preliminary Efficacy of UCL70805F in the Treatment of Patients With CD70-positive Advanced Renal Clear Cell Carcinoma
Latest Information Update: 06 Apr 2026
At a glance
- Drugs UCL 70805F (Primary) ; Cyclophosphamide; Fludarabine
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors UTC Therapeutics
Most Recent Events
- 06 Apr 2026 New trial record